A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report

BACKGROUND: Expanding the druggable novel anaplastic lymphoma kinase (ALK) fusions list is crucial to the precise treatment of patients with cancer with positive ALK fusions. The intergenic-ALK fusions accounted for a substantial proportion of ALK fusions. However, they were typically considered of...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Jia, Wang, Baoming, Li, Mengxia, Wang, Chunyang, Ma, Tonghui, Shan, Jinlu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280124/
https://www.ncbi.nlm.nih.gov/pubmed/35847849
http://dx.doi.org/10.3389/fonc.2022.898954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280124/
https://www.ncbi.nlm.nih.gov/pubmed/35847849
http://dx.doi.org/10.3389/fonc.2022.898954

Ejemplares similares